PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/68, C12N 5/00, 15/79, C07H 21/04 — A1

(11) International Publication Number: WO 97/44490

(43) International Publication Date: 27 November 1997 (27.11.97)

(21) International Application Number: PCT/US97/09356

(22) International Filing Date: 21 May 1997 (21.05.97)

(30) Priority Data:
08/652,207 23 May 1996 (23.05.96) US

(71) Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 North Walnut Street, P.O. Box 7365, Madison, WI 53707-7365 (US).

(72) Inventors: CHANG, Chawnshang; 209 Acadia Drive, Madison, WI 53717 (US). YEH, Shuyuan; 209 Eagle Heights #B, Madison, WI 53705 (US).

(74) Agent: SEAY, Nicholas, J.; Quarles & Brady, P.O. Box 2113, Madison, WI 53701-2113 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: SPECIFIC CO-ACTIVATOR FOR HUMAN ANDROGEN RECEPTOR

(57) Abstract

A ligand dependent co-activator for the human androgen receptor has been identified. The co-activator, named here ARA_{70}, potentiates interaction between androgens and the receptor. The co-activator is useful as a tool in monitoring the androgenic/antiandrogenic effects of possible pharmaceuticals as well as environmental samples. The cDNA for co-activator has been cloned and sequenced.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SPECIFIC CO-ACTIVATOR FOR HUMAN ANDROGEN RECEPTOR

Field of the Invention

The present invention relates to a cloned gene for a protein which co-activates an important hormonal receptor in humans and relates, in addition, to the use of the co-activator protein as an important constituent in clinical tests for diagnoses of human clinical conditions.

Background of the Invention

The class of compounds known as androgens are the hormonal signals responsible for maleness in mammals in general and human beings in particular. As with most hormonal signals, androgens interact with their targets by binding to a receptor, known as the androgen receptor. Recognition of androgens by the androgen receptor initiates a series of transcriptional events giving rise to male-associated processes in certain tissues and organs. The binding of androgens to the androgen receptor is also important in many androgen related diseases and conditions, such as baldness and acne, as well as important clinical diseases such as prostate cancer. The androgen receptor belongs to the steroid receptor super family that plays an important role in male sexual differentiation and prostate cell proliferation. Mutations or abnormal expressions of the androgen receptor in prostate cells may play an important role in the progression of prostate cancer.

When bound to androgens and androgen responsive elements, the androgen receptor can up-regulate or down-regulate the expression of androgen target genes through a complicated process that may involve multiple adaptors or co-activators. Adler et al., Proc. Natl. Acad. Sci. USA 89, 6319-6325 (1992). A fundamental issue in the field of steroid hormone regulation is the question or how specific androgen-activated transcription can be achieved *in vivo* when several different

receptors recognize the same DNA sequence. For example, the androgen receptor (AR), the glucocorticoid receptor (GR) and the progesterone receptor (PR) all recognize the same sequence but activate different transcription activities. It has been speculated by some that accessory factors may selectively interact with the androgen receptor to determine the specificity of the androgen receptor target gene activation.

One of the uses for the androgen receptor is to detect the androgenic or anti-androgenic effects of specific candidate human pharmaceutical molecules. The androgenic effect of pharmaceuticals is usually an attribute of potential candidate therapeutic medicines that must be evaluated during the process of total evaluation of a molecule for human therapeutic value. Accordingly, the androgen receptor is used in screens to determine the frequency and specificity by which specific molecules bind to such receptors.

Summary of the Invention

The present invention is summarized in that a specific co-activator for the human androgen receptor has been isolated and the gene for that co-activator has been cloned sequenced and is presented below.

The present invention is also summarized in that the cloning and reproduction of the androgen receptor activator gene permits new laboratory tests to be made to test the androgen specificity of candidate therapeutic molecules.

Other objects, advantages, and features of the present invention will become apparent from the following specification.

Brief Description of the Drawings

Fig. 1 is a schematic illustration of the use of the yeast two-hybrid system as used to identify ARA_{70}.

Description of the Invention

The present invention is enabled by a discovery of a new regulatory protein in humans. This regulatory protein is the

androgen receptor associated protein, here designated ARA_{70}, which is a co-activator for the androgen receptor in human prostate cells. The ARA_{70} factor is a ligand dependent protein that functions as a specific co-activator to enhance the transcriptional effect of androgen binding to the androgen receptor and also facilitates binding and activation of the androgen receptor by molecules previously not thought to have androgenic character.

Using a yeast two hybrid system, as described below, a cDNA encoding the ARA_{70} molecule has been recovered from human prostate cells. The recovered ARA_{70} cDNA encodes a protein of 614 amino acids, with a calculated molecular weight of 70 kilodaltons. The full length cDNA has fully been sequenced, and the sequence is presented as SEQ ID NO 1 below. A search of the GenBank indicates that the ARA_{70} cDNA shares a high degree of homology (99%) with a previously identified cDNA clone (RET-fused gene RFG), isolated from human thyroid as reported by Santoro et al., Oncogene 9, 509-516 (1994). Santoro et al. were unable to identify the main biological functions of the protein designated RFG, although the expression of the RFG in thyroid tumor suggests a potential role for the RFG molecule in thyroid carcinogenesis.

Northern Blot analysis indicated that the ARA_{70} co-activator transcript is present in many tissues, including prostate, testis, adrenal gland, and thymus. Most human cell lines tested positive for the ARA_{70} co-factor, with the significant exception of a human prostate cancer cell line, which did not express the ARA_{70} molecule.

A specific ligand is necessary to actuate the co-activator role of ARA_{70} as an enhancer of androgen receptor transcriptional activity. The most potent ligand yet identified is dihydrotestosterone (DHT). Using the yeast two hybrid model system, it has been demonstrated that the ARA_{70} molecule will enhance the transcriptional activity actuated by androgen binding to the androgen receptor 10 to 58 fold, as measured in the presence of 10^{-10} M DHT. Furthermore, as described in greater detail below, the transcriptional activity

of AR was activated by ARA_{70} in the presence of 10^{-8} M 17β-estradiol (E2) in human prostate cells, but did not have the same enhancement of transcriptional activity in the presence of 10^{-6} M diethylstilbestrol (DES) an estrogen thought to be more potent. This data suggests that co-activators, such as ARA_{70}, for androgen receptor activity can mediate transcriptional activation of molecules previously thought to be essentially non-androgenic in a manner not previously detectable.

The availability of the ARA_{70} cDNA clone described below enables the production of ARA_{70} in foreign hosts. By joining the ARA_{70} coding region to a promoter effective to initiate transcriptional activity in a desired host, whether eukaryotic or prokaryotic cells, quantities of ARA_{70} can be manufactured in a foreign host for the uses described here and for other uses.

It is specifically envisioned that ARA_{70} will have particular use as a constituent in a drug testing or screening protocol. It is a general practice in the evaluation of new clinical compounds for pharmaceutical utility that the compounds be tested for androgenic activity. Androgenic or antiandrogenic side effects can be important in the administration of some pharmaceutical agents. Previously, one of the methods used to test androgen activity was testing for binding and activation of the androgen receptor transcriptional activity. As the data herein suggests, the presence of ARA_{70} in the presence of the androgen receptor greatly alters both the magnitude and the specificity of the transcriptional effect of androgen binding to the AR receptor elicited by specific androgens. In addition, as evidenced with the estrogen E2 indicates, some molecules previously thought not to have androgenic activity will, in the presence of ARA_{70}, initiate transcriptional activity when bound to the androgen receptor and some molecules previously thought not to have inhibitory effect will limit or oppose the activity of the androgen receptor activated by ARA_{70}. Accordingly, in testing potential pharmaceutical molecules for androgenic or antiandrogenic effect, it would be important to include ARA_{70} in the assay for androgenic/antiandrogenic activity to fully test androgenic

effects actuated by the candidate molecule *in vivo*.

It is also anticipated that ARA_{70} will serve as a clinical indicator of significant important for androgen related diseases. Significant androgen related diseases, such as prostate cancer, baldness, acne, and androgen insensitive syndromes, such as TMF syndrome, may be due to defects in the co-activation mechanism between the androgen receptor and the ARA_{70} molecule. Accordingly, it becomes a reasonable possibility, given the data presented herein, to assay the relative ratios of AR and ARA_{70} in patients with such conditions. Such ratios may be measured by raising antibodies to both ARA_{70} and to AR in performing quantitative methods to adjudge the relative quantity of the two molecules in a particular patient. Several methods exist for measuring such comparative ratios, including radio immunoassay, ELISA, immunostaining, or Western Blot. In addition, it would be possible to use the ARA_{70} cDNA so as to construct probes for PCR assay for the presence of mutations of the normal DNA sequence in particular patients, or to generate transcript for Northern Blot assay or DNA for *in situ* hybridization assays.

The theory for such measurements of relative ratios of ARA to ARA_{70} is that androgen insensitive related disease may be due to an imbalance between androgen receptor and androgen ARA_{70} prevalence in target cells. Too much ARA_{70} might over-sensitize the androgen receptor system, so as to be responsive to molecules not intended to have androgenic effect. Under sensitivity due to absence or non-function of ARA_{70} may lead to androgen insensitivity at any levels. If too much ARA_{70} was found to be present in a particular patient, that would suggest the use of down regulation mechanisms such as antisense or other similar mechanisms, in clinical system so as to reduce the levels of ARA_{70} prevalent in a particular patient. If a particular patient had too little ARA_{70}, then it would be possible to deliver ARA_{70} cDNA, protein, or DNA, into a patient by a variety of delivery mechanisms to increase levels of active ARA_{70} in the patient.

In addition to testing potential pharmaceutical uses, the

ARA_{70} molecule would be useful for testing non-pharmaceutical compounds for potential androgenic/antiandrogenic activity. It is currently believed that many contaminants present within the environment at low samples have androgenic/antiandrogenic or estrogenic/antiestrogenic activity on various parts of the population. Since the ARA_{70} increases androgen receptor specificity by over 10 fold, the sensitivity of androgen receptor tests can be greatly enhanced by the use of ARA_{70} in such assay systems. As demonstrated by the fact that the addition of ARA_{70} causes compounds classically thought to be only estrogenic, such as 17β estradiol, to exhibit androgenic activity, and by the fact that compounds thought to be only antiestrogenic, such as tamoxifen, can exhibit antiandrogenic activity, tests for androgenic/antiandrogenic activity would be incomplete without the use of ARA_{70} as a co-factor in such reactions.

To test samples for androgenic/antiandrogenic activity, genetic constructions including expression cassettes for both the androgen receptor and ARA_{70} would be transformed into host cells, such as a prostate cell line, *in vitro*. Also an easily detectable and quantifiable detector gene would be transformed in the cells as well. A suitable detector gene would be chloramphenicol acetyltransferase, or CAT, or luciferase the expression of which can be detected photometrically. The cells are then exposed to the pharmaceutical agent or environmental sample. Samples with androgenic/antiandrogenic activity will actuate increased or decreased detectable levels of CAT or luciferase activity.

Examples

Identification of the Androgen Receptor Specific-Associated Protein, ARA_{70}. To understand the mechanism of androgen-AR action, a yeast two-hybrid system, using the GAL4AR fusion protein as bait, was used to isolate a cDNA encoding ARA_{70} which interacts specifically with AR. The fusion protein GAL4AR contains the GAL4 DNA binding domain (GAL4DBD) fused to the C-terminus of the androgen receptor. The fusion protein

was used to screen for His-synthase gene positive clones from 3 x 10^6 transformants of the MATCHMAKER human brain library. Two of the initial 41 putatively positive clones clearly reacted with the AR fusion protein, by liquid assays performed by the method of Durfee et al. Genes & Dev. 7, 555-569 (1993).

In this yeast two-hybrid system, illustrated schematically in Fig. 1, yeast will survive when GAL4AR is co-expressed with ARA_{70} in the presence of DHT. Neither GAL4AR nor ARA_{70} was active when ARA_{70} was expressed alone or when ARA_{70} was co-expressed with GAL4RAR or GAL4TR4, Chang et al. Proc. Natl. Acad. Sci. USA, 91, 6040-6044 (1994), (GAL4 fusion proteins with two other members of the steroid receptor superfamily). These data, therefore, clearly suggest that ARA_{70} can interact specifically with AR in the yeast cells.

We then tested whether the interaction of ARA_{70} with AR in yeast was ligand-dependent. It was found that DHT (5 x 10^{-10}M) can promote the interaction between ARA_{70} and GAL4AR. Testosterone (T), a less potent androgen in the prostate, can also promote this interaction at higher concentrations (5 x 10^{-9}M). Hydroxyflutamide (HF), an antiandrogen used in the treatment of prostate cancer, had no activity even at very high concentrations (10^{-5}M).

The RACE-PCR technique (10,11) was then used to clone the full-length ARA_{70} cDNA, encoding a protein of 615 amino acids with a calculated molecular weight of 70 K, (SEQ ID NO 1 & 2). A search of GenBank indicated that ARA_{70} shares 99% homology (three different amino acids in the coding region) with one identified cDNA clone (RET-fused gene, RFG) isolated from human thyroid. Although the biological functions of RFG are mostly unknown, the expression of RFG in thyroid tumor may suggest some potential roles of RFG in thyroid carcinogenesis.

The Tissue Distribution of ARA_{70}. Northern blot analysis in mouse indicated that ARA_{70} is expressed as an mRNA of ~3600 bp in many tissues, including prostate, testis, adrenal gland, and thymus. The relative expression of ARA_{70} in the following mouse tissues, using adrenal gland as 100%, are: testis, 77%; prostate, 97%; preputial gland, 64%, thymus, 214%; submaxillary

gland, 24%; muscle, 41%, heart, 73%; kidney, 37%; lung, 49%; fat pad, 20%; seminal vesicle and spleen undetectable. Among the cell lines (LNCaP, MCF-7, CHO, HeLa and DU145) tested, the human prostate cancer cell line, DU145, proved to be the only cell line that did not express ARA_{70}, and therefore was chosen for further functional study.

The *In Vitro* Interaction Between AR and ARA_{70}. To further confirm that the interaction that occurred in yeast cells is due to a direct interaction between AR and ARA_{70}, we applied an *in vitro* immunoprecipitation assay with an anti-AR antibody designated CW2. We demonstrated that CW2 can co-precipitate the AR and ARA_{70} when *in vitro* transcribed/translated full-length human AR and ARA_{70} were incubated with it in a lysate mixture. This precipitation is specific, as CW2 did not precipitate the ARA_{70} in the absence of AR and CW2 did not precipitate two other proteins (RXR and TR4 orphan receptors) incubated with AR. A Far-Western assay also demonstrated that ARA_{70} can bind to immobilized AR peptide containing DNA binding domain and hormone binding domain (AR-DBD/HBD), but not the BL21 protein lysate or the AR peptide containing the N-terminal and DNA binding domain of AR (AR-N/DBD). This data indicates that the association is due to a direct interaction between AR and ARA_{70}.

To perform the Far-Western assay, AR-N/DBD and AR-DBD/HBD were expressed, as polyhistidine fusion proteins by inserting the N-terminal or C-terminal fragments into pET 14b (Novagen). Proteins were separated on 10% polyacrylamide gel. ^{35}S-labeled ARA_{70} was diluted into hybridization buffer and the titers were hybridized overnight in the presence of 1 μM DHT. After three washings, filters were dried and autoradiographs made.

Stimulation of the Transcriptional Activity of AR by ARA_{70}. DU145 cells were co-transfected with ARA_{70} and AR under the control of a eukaryotic promoter. Ligand-free AR was found to have minimal MMTV-ARE CAT reporter activity, with or without the presence of ARA_{70}. Addition of DHT resulted in a 6-fold increase of AR activity. This transcriptional activity was increased 58 ($\pm$ 3.2)-fold (mean $\pm$ SEM; n=4) by the co-

transfection of ARA_{70} cDNAs in a dose-dependent manner. The induced activity reached a plateau at 4.5 μg of co-transfected ARA_{70} cDNA. Additional ARA_{70}, beyond 4.5 μg, (up to 6μg) did not affect the induced activity of AR in DU145 cells. To rule out any indirect effects on the basal activity of the MMTV-ARE CAT reporter, we removed the ARE DNA fragment from the reporter (MMTV-ΔARE-CAT). The results showed that ARA_{70} induced no activity on this reporter in the presence or in the absence of DHT.

We also replaced ARA_{70} with another nuclear orphan receptor-associated protein, TR4AP, in the AR: MMTV-ARE CAT reporter assay and found this protein had no effect in our assay. Furthermore, when we replaced DU145 cells with CHO cells, which express a relative abundance of ARA_{70}, we found that although the exogenously transfected ARA_{70} did not show a dramatic effect on induction of AR transcriptional activity, the transfection of antisense ARA_{70} did partially block the AR transcriptional activity. Together, these data strongly suggest that stimulation of AR transcriptional activity by ARA_{70} occurs through a specific ligand-bound AR and the relative amount of AR vs ARA_{70} in cells plays an important role for the activation of AR.

The effect of ARA_{70} on transactivation of AR bound to different concentrations of testosterone (T), dihydrotestorenone (DHT) and hydroxy flutamide (HF) in DU145 cells was also tested. Whereas 10^{-10} M DHT maximized induced transcriptional activity of AR, with T a 10-fold higher concentration (10^{-9} M) was needed for maximum activity. HF induced very low at a pharmacological concentration (10^{-6} M). These results are consistent with the data generated from yeast cells and previous reports, which indicated DHT is more potent androgen in the prostate. In fact, the greater potency of DHT to modulate the interaction between AR and ARA_{70} may actually provide the reason why DHT is a more potent androgen in prostate.

The enhancement of AR transcriptional activity from 6-fold to 58-fold by ARA_{70} may explain androgen activity in the

prostate that androgen-AR alone cannot explain. Since we detected ARA_{70} in AR-positive LNCaP prostate cancer cells, but not in AR-negative DU145 cells, it will be important to determine if the expression of ARA_{70} and its ability to interact properly with androgen-AR changes during the progression of prostate cancer from an androgen-dependent to an androgen-independent state.

ARA_{70} Functions As a Specific Activator to Enhance the Transcriptional Activity of AR. We also examined the effect of ARA_{70} on the transcriptional activity of several other steroid receptors through their cognate DNA response elements. While ARA_{70} induces the transcriptional activity of AR up to 10-fold, ARA_{70} can only slightly enhance (up to 2-fold) the transcription activity of other steroid receptors, such as GR, PR, and ER. These results clearly indicate that ARA_{70} is a very specific co-activator for AR.

Several proteins have been demonstrated to interact with other steroid receptors in a ligand-dependent or ligand-independent manner. However, none of these proteins have been shown to enhance specifically AR-mediated transcriptional activity; therefore, it is likely that ARA_{70} has a different mechanism for interacting with AR.

In summary, our data demonstrated that ARA_{70} is the first identified ligand-dependent associated protein for AR which may function as a specific co-activator for inducing the transcriptional activity of AR in human prostate cells. Further studying the potential role of ARA_{70} may therefore help us to understand better the molecular mechanism of androgen action.

Transcriptional Activity of AR Induced by 17β-estradiol

Tests in both DU145 cells and yeast cells demonstrated that 17β-estradiol, at a concentration of 10^{-8} M or higher, stimulated the transcriptional activity of AR in the presence of ARA_{70}. By contrast, diethylstilbestrol (DES), even at concentrations of 10^{-6} M, did not increase AR transcriptional activity. This result may explain why DES, but not 17β-estradiol, has fewer side effects when used by clinicians to

treat prostate cancer patients.

Antiandrogenic Activity of Tamoxifen and ICI_{IP2780}

Similar protocols were repeated but, instead of adding an androgen or estrogen, tamoxifen and ICI_{IP2780} were added, both compounds known to be antiestrogenic. The data revealed that both compounds inhibited AR initiated transcriptional activity in human prostate cells. This demonstrates the ability to assay for antiandrogenic effects using this same style of assay.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Chang, Chawnshang
Yeh, Shuyuan

(ii) TITLE OF INVENTION: Specific Co-Activator for Human Androgen Receptor

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Quarles & Brady
(B) STREET: 1 South Pinckney Street
(C) CITY: Madison
(D) STATE: WI
(E) COUNTRY: US
(F) ZIP: 53703

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Seay, Nicholas J
(B) REGISTRATION NUMBER: 27386
(C) REFERENCE/DOCKET NUMBER: 960296.93871

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 608-251-5000
(B) TELEFAX: 251-9166

(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1845 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1845

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
ATG AAT ACC TTC CAA GAC CAG AGT GGC AGC TCC AGT AAT AGA GAA CCC   48
Met Asn Thr Phe Gln Asp Gln Ser Gly Ser Ser Ser Asn Arg Glu Pro
 1               5                  10                  15

CTT TTG AGG TGT AGT GAT GCA CGG AGG GAC TTG GAG CTT GCT ATT GGT   96
Leu Leu Arg Cys Ser Asp Ala Arg Arg Asp Leu Glu Leu Ala Ile Gly
            20                  25                  30
```

```
GGA GTT CTC CGG GCT GAA CAG CAA ATT AAA GAT AAC TTG CGA GAG GTC  144
Gly Val Leu Arg Ala Glu Gln Gln Ile Lys Asp Asn Leu Arg Glu Val
          35                  40                  45

AAA GCT CAG ATT CAC AGT TGC ATA AGC CGT CAC CTG GAA TGT CTT AGA  192
Lys Ala Gln Ile His Ser Cys Ile Ser Arg His Leu Glu Cys Leu Arg
      50                  55                  60

AGC CGT GAG GTA TGG CTG TAT GAA CAG GTG GAC CTT ATT TAT CAG CTT  240
Ser Arg Glu Val Trp Leu Tyr Glu Gln Val Asp Leu Ile Tyr Gln Leu
 65                  70                  75                  80

AAA GAG GAG ACA CTT CAA CAG CAG GCT CAG CAG CTC TAC TCG TTA TTG  288
Lys Glu Glu Thr Leu Gln Gln Gln Ala Gln Gln Leu Tyr Ser Leu Leu
                 85                  90                  95

GGC CAG TTC AAT TGT CTT ACT CAT CAA CTG GAG TGT ACC CAA AAC AAA  336
Gly Gln Phe Asn Cys Leu Thr His Gln Leu Glu Cys Thr Gln Asn Lys
            100                 105                 110

GAT CTA GCC AAT CAA GTC TCT GTG TGC CTG GAG AGA CTG GGC AGT TTG  384
Asp Leu Ala Asn Gln Val Ser Val Cys Leu Glu Arg Leu Gly Ser Leu
        115                 120                 125

ACC CTT AAG CCT GAA GAT TCA ACT GTC CTG CTC TTT GAA GCT GAC ACA  432
Thr Leu Lys Pro Glu Asp Ser Thr Val Leu Leu Phe Glu Ala Asp Thr
    130                 135                 140

ATT ACT CTG CGC CAG ACC ATC ACC ACA TTT GGG TCT CTC AAA ACC ATT  480
Ile Thr Leu Arg Gln Thr Ile Thr Thr Phe Gly Ser Leu Lys Thr Ile
145                 150                 155                 160

CAA ATT CCT GAG CAC TTG ATG GCT CAT GCT AGT TCA GCA AAT ATT GGG  528
Gln Ile Pro Glu His Leu Met Ala His Ala Ser Ser Ala Asn Ile Gly
                165                 170                 175

CCC TTC CTG GAG AAG AGA GGC TGT ATC TCC ATG CCA GAG CAG AAG TCA  576
Pro Phe Leu Glu Lys Arg Gly Cys Ile Ser Met Pro Glu Gln Lys Ser
            180                 185                 190

GCA TCC GGT ATT GTA GCT GTC CCT TTC AGC GAA TGG CTC CTT GGA AGC  624
Ala Ser Gly Ile Val Ala Val Pro Phe Ser Glu Trp Leu Leu Gly Ser
        195                 200                 205

AAA CCT GCC AGT GGT TAT CAA GCT CCT TAC ATA CCC AGC ACC GAC CCC  672
Lys Pro Ala Ser Gly Tyr Gln Ala Pro Tyr Ile Pro Ser Thr Asp Pro
    210                 215                 220

CAG GAC TGG CTT ACC CAA AAG CAG ACC TTG GAG AAC AGT CAG ACT TCT  720
Gln Asp Trp Leu Thr Gln Lys Gln Thr Leu Glu Asn Ser Gln Thr Ser
225                 230                 235                 240

TCC AGA GCC TGC AAT TTC TTC AAT AAT GTC GGG GGA AAC CTA AAG GGC  768
Ser Arg Ala Cys Asn Phe Phe Asn Asn Val Gly Gly Asn Leu Lys Gly
                245                 250                 255

TTA GAA AAC TGG CTC CTC AAG AGT GAA AAA TCA AGT TAT CAA AAG TGT  816
Leu Glu Asn Trp Leu Leu Lys Ser Glu Lys Ser Ser Tyr Gln Lys Cys
            260                 265                 270

AAC AGC CAT TCC ACT ACT AGT TCT TTC TCC ATT GAA ATG GAA AAG GTT  864
Asn Ser His Ser Thr Thr Ser Ser Phe Ser Ile Glu Met Glu Lys Val
        275                 280                 285

GGA GAT CAA GAG CTT CCT GAT CAA GAT GAG ATG GAC CTA TCA GAT TGG  912
Gly Asp Gln Glu Leu Pro Asp Gln Asp Glu Met Asp Leu Ser Asp Trp
    290                 295                 300
```

```
CTA GTG ACT CCC CAG GAA TCC CAT AAG CTG CGG AAG CCT GAG AAT GGC  960
Leu Val Thr Pro Gln Glu Ser His Lys Leu Arg Lys Pro Glu Asn Gly
305                 310                 315                 320

AGT CGT GAA ACC AGT GAG AAG TTT AAG CTC TTA TTC CAG TCC TAT AAT 1008
Ser Arg Glu Thr Ser Glu Lys Phe Lys Leu Leu Phe Gln Ser Tyr Asn
                325                 330                 335

GTG AAT GAT TGG CTT GTC AAG ACT GAC TCC TGT ACC AAC TGT CAG GGA 1056
Val Asn Asp Trp Leu Val Lys Thr Asp Ser Cys Thr Asn Cys Gln Gly
            340                 345                 350

AAC CAG CCC AAA GGT GTG GAG ATT GAA AAC CTG GGC AAT CTG AAG TGC 1104
Asn Gln Pro Lys Gly Val Glu Ile Glu Asn Leu Gly Asn Leu Lys Cys
        355                 360                 365

CTG AAT GAC CAC TTG GAG GCC AAG AAA CCA TTG TCC ACC CCC AGC ATG 1152
Leu Asn Asp His Leu Glu Ala Lys Lys Pro Leu Ser Thr Pro Ser Met
    370                 375                 380

GTT ACA GAG GAT TGG CTT GTC CAG AAC CAT CAG GAC CCA TGT AAG GTA 1200
Val Thr Glu Asp Trp Leu Val Gln Asn His Gln Asp Pro Cys Lys Val
385                 390                 395                 400

GAG GAG GTG TGC AGA GCC AAT GAG CCC TGC ACA AGC TTT GCA GAG TGT 1248
Glu Glu Val Cys Arg Ala Asn Glu Pro Cys Thr Ser Phe Ala Glu Cys
                405                 410                 415

GTG TGT GAT GAG AAT TGT GAG AAG GAG GCT CTG TAT AAG TGG CTT CTG 1296
Val Cys Asp Glu Asn Cys Glu Lys Glu Ala Leu Tyr Lys Trp Leu Leu
            420                 425                 430

AAG AAA GAA GGA AAG GAT AAA AAT GGG ATG CCT GTG GAA CCC AAA CCT 1344
Lys Lys Glu Gly Lys Asp Lys Asn Gly Met Pro Val Glu Pro Lys Pro
        435                 440                 445

GAG CCT GAG AAG CAT AAA GAT TCC CTG AAT ATG TGG CTC TGT CCT AGA 1392
Glu Pro Glu Lys His Lys Asp Ser Leu Asn Met Trp Leu Cys Pro Arg
    450                 455                 460

AAA GAA GTA ATA GAA CAA ACT AAA GCA CCA AAG GCA ATG ACT CCT TCT 1440
Lys Glu Val Ile Glu Gln Thr Lys Ala Pro Lys Ala Met Thr Pro Ser
465                 470                 475                 480

AGA ATT GCT GAT TCC TTC CAA GTC ATA AAG AAC AGC CCC TTG TCG GAG 1488
Arg Ile Ala Asp Ser Phe Gln Val Ile Lys Asn Ser Pro Leu Ser Glu
                485                 490                 495

TGG CTT ATC AGG CCC CCA TAC AAA GAA GGA AGT CCC AAG GAA GTG CCT 1536
Trp Leu Ile Arg Pro Pro Tyr Lys Glu Gly Ser Pro Lys Glu Val Pro
            500                 505                 510

GGT ACT GAA GAC AGA GCT GGC AAA CAG AAG TTT AAA AGC CCC ATG AAT 1584
Gly Thr Glu Asp Arg Ala Gly Lys Gln Lys Phe Lys Ser Pro Met Asn
        515                 520                 525

ACT TCC TGG TGT TCC TTT AAC ACA GCT GAC TGG GTC CTG CCA GGA AAG 1632
Thr Ser Trp Cys Ser Phe Asn Thr Ala Asp Trp Val Leu Pro Gly Lys
    530                 535                 540

AAG ATG GGC AAC CTC AGC CAG TTA TCT TCT GGA GAA GAC AAG TGG CTG 1680
Lys Met Gly Asn Leu Ser Gln Leu Ser Ser Gly Glu Asp Lys Trp Leu
545                 550                 555                 560

CTT CGA AAG AAG GCC CAG GAA GTA TTA CTT AAT TCA CCT CTA CAG GAG 1728
Leu Arg Lys Lys Ala Gln Glu Val Leu Leu Asn Ser Pro Leu Gln Glu
                565                 570                 575
```

```
GAA CAT AAC TCC CCC CCA GAC CAT TAT GGC CTC CCT GCA GTT TGT GAT 1776
Glu His Asn Ser Pro Pro Asp His Tyr Gly Leu Pro Ala Val Cys Asp
            580                 585                 590

CTC TTT TCC TGT ATG CAG CTT AAA GTT GAT AAA GAG AAG TGG TTA TAT 1824
Leu Phe Ser Cys Met Gln Leu Lys Val Asp Lys Glu Lys Trp Leu Tyr
        595                 600                 605

CAG ACT CCT CTA CAG ATG TGA                                 1845
Gln Thr Pro Leu Gln Met  *
    610                 615
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 614 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Asn Thr Phe Gln Asp Gln Ser Gly Ser Ser Ser Asn Arg Glu Pro
 1               5                  10                  15

Leu Leu Arg Cys Ser Asp Ala Arg Arg Asp Leu Glu Leu Ala Ile Gly
            20                  25                  30

Gly Val Leu Arg Ala Glu Gln Gln Ile Lys Asp Asn Leu Arg Glu Val
        35                  40                  45

Lys Ala Gln Ile His Ser Cys Ile Ser Arg His Leu Glu Cys Leu Arg
    50                  55                  60

Ser Arg Glu Val Trp Leu Tyr Glu Gln Val Asp Leu Ile Tyr Gln Leu
65                  70                  75                  80

Lys Glu Glu Thr Leu Gln Gln Gln Ala Gln Gln Leu Tyr Ser Leu Leu
                85                  90                  95

Gly Gln Phe Asn Cys Leu Thr His Gln Leu Glu Cys Thr Gln Asn Lys
            100                 105                 110

Asp Leu Ala Asn Gln Val Ser Val Cys Leu Glu Arg Leu Gly Ser Leu
        115                 120                 125

Thr Leu Lys Pro Glu Asp Ser Thr Val Leu Leu Phe Glu Ala Asp Thr
    130                 135                 140

Ile Thr Leu Arg Gln Thr Ile Thr Thr Phe Gly Ser Leu Lys Thr Ile
145                 150                 155                 160

Gln Ile Pro Glu His Leu Met Ala His Ala Ser Ser Ala Asn Ile Gly
                165                 170                 175

Pro Phe Leu Glu Lys Arg Gly Cys Ile Ser Met Pro Glu Gln Lys Ser
            180                 185                 190

Ala Ser Gly Ile Val Ala Val Pro Phe Ser Glu Trp Leu Leu Gly Ser
        195                 200                 205

Lys Pro Ala Ser Gly Tyr Gln Ala Pro Tyr Ile Pro Ser Thr Asp Pro
    210                 215                 220
```

Gln Asp Trp Leu Thr Gln Lys Gln Thr Leu Glu Asn Ser Gln Thr Ser
225 230 235 240

Ser Arg Ala Cys Asn Phe Phe Asn Asn Val Gly Gly Asn Leu Lys Gly
245 250 255

Leu Glu Asn Trp Leu Leu Lys Ser Glu Lys Ser Ser Tyr Gln Lys Cys
260 265 270

Asn Ser His Ser Thr Thr Ser Ser Phe Ser Ile Glu Met Glu Lys Val
275 280 285

Gly Asp Gln Glu Leu Pro Asp Gln Asp Glu Met Asp Leu Ser Asp Trp
290 295 300

Leu Val Thr Pro Gln Glu Ser His Lys Leu Arg Lys Pro Glu Asn Gly
305 310 315 320

Ser Arg Glu Thr Ser Glu Lys Phe Lys Leu Leu Phe Gln Ser Tyr Asn
325 330 335

Val Asn Asp Trp Leu Val Lys Thr Asp Ser Cys Thr Asn Cys Gln Gly
340 345 350

Asn Gln Pro Lys Gly Val Glu Ile Glu Asn Leu Gly Asn Leu Lys Cys
355 360 365

Leu Asn Asp His Leu Glu Ala Lys Lys Pro Leu Ser Thr Pro Ser Met
370 375 380

Val Thr Glu Asp Trp Leu Val Gln Asn His Gln Asp Pro Cys Lys Val
385 390 395 400

Glu Glu Val Cys Arg Ala Asn Glu Pro Cys Thr Ser Phe Ala Glu Cys
405 410 415

Val Cys Asp Glu Asn Cys Glu Lys Glu Ala Leu Tyr Lys Trp Leu Leu
420 425 430

Lys Lys Glu Gly Lys Asp Lys Asn Gly Met Pro Val Glu Pro Lys Pro
435 440 445

Glu Pro Glu Lys His Lys Asp Ser Leu Asn Met Trp Leu Cys Pro Arg
450 455 460

Lys Glu Val Ile Glu Gln Thr Lys Ala Pro Lys Ala Met Thr Pro Ser
465 470 475 480

Arg Ile Ala Asp Ser Phe Gln Val Ile Lys Asn Ser Pro Leu Ser Glu
485 490 495

Trp Leu Ile Arg Pro Pro Tyr Lys Glu Gly Ser Pro Lys Glu Val Pro
500 505 510

Gly Thr Glu Asp Arg Ala Gly Lys Gln Lys Phe Lys Ser Pro Met Asn
515 520 525

Thr Ser Trp Cys Ser Phe Asn Thr Ala Asp Trp Val Leu Pro Gly Lys
530 535 540

Lys Met Gly Asn Leu Ser Gln Leu Ser Ser Gly Glu Asp Lys Trp Leu
545 550 555 560

Leu Arg Lys Lys Ala Gln Glu Val Leu Leu Asn Ser Pro Leu Gln Glu
565 570 575

```
Glu His Asn Ser Pro Pro Asp His Tyr Gly Leu Pro Ala Val Cys Asp
            580                 585                 590

Leu Phe Ser Cys Met Gln Leu Lys Val Asp Lys Glu Lys Trp Leu Tyr
        595                 600                 605

Gln Thr Pro Leu Gln Met  *
    610                 615
```

CLAIMS

1. A constructed DNA sequence comprising 5' to 3'
a promoter effective in cells of a host to cause expression of a protein coding region;
a protein coding region for a human ARA_{70} protein; and
the promoter and the protein coding region not natively associated with each other.

2. A eukaryotic host cell hosting the DNA sequence of Claim 1.

3. An isolated DNA sequence apart from a host comprising the sequence of SEQ ID NO. 1.

4. A constructed DNA sequence comprising 5' to 3'
a promoter effective in cells of a host to cause expression of a protein coding region;
a protein coding region coding for a protein having the sequence of SEQ ID NO 2.; and
the promoter and the protein coding region not natively associated with each other.

5. A eukaryotic host cell hosting the DNA sequence of Claim 4.

6. A method for testing the androgenic or antiandrogenic effect of a chemical compound comprising the steps of

transforming host cells with a genetic construction effective in that host cell to produce both human androgen receptor protein and ARA_{70} protein;

exposing the transformed host cells to the chemical compound; and

measuring the level of transcriptional activity caused by the androgen receptor.

7. The method of Claim 6 wherein the host cells are prostate cells.

8. The method of Claim 6 wherein genetic construction producing the ARA_{70} protein has the DNA sequence of SEQ ID NO. 1.

9. The method of Claim 6 wherein the genetic construction also includes a reported gene, the expression of which can be easily detected and quantified.

10. The method of Claim 9 wherein the reporter gene is the CAT gene.

11. The method of Claim 6 wherein the chemical compound is a pharmaceutical.

12. The method of Claim 6 wherein the chemical compound is contained in an environmental sample.

13. A method of diagnosing the androgen responsiveness of a human patient, comprising the steps of

taking a sample of cells or body fluid from the patient;

testing the sample for levels of androgen receptor;

testing the sample for levels of ARA_{70}; and

using the relative ratio between the levels of androgen receptor and ARA_{70} as an indication of normality or abnormality of androgen sensitivity in the patient.

a



FIG 1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/09356

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/68; C12N 5/00, 15/79; C07H 21/04
US CL :435/6, 320.1, 325; 536/23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 320.1, 325; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: Medline, Biosis. Embase, CAPlus, WPIDS, JAPIO, PATOSEP, PATOSWO
search terms: ARA70, androgen receptor, coactivator

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	YEH et al. Cloning and characterization of a specific coactivator, ARA_{70}, for the androgen receptor in human prostate cells. Proc. Natl. Acad. Sci. USA. May 1996. Vol. 93. pages 5517-5521. See entire document.	1-13

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 11 JULY 1997	Date of mailing of the international search report 26 AUG 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer ROBERT SCHWARTZMAN Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*